<DOC>
	<DOCNO>NCT01190410</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety tolerability certolizumab pegol ( CZP ) treatment child adolescent moderately severely active Crohn 's disease . Secondarily , assess long-term efficacy , pharmacokinetics ( PK ) , immunogenicity CZP treatment child adolescent moderately severely active Crohn 's disease .</brief_summary>
	<brief_title>Extension Study Assess Long Term Safety Children Adolescents With Crohn 's Disease Receiving Certolizumab Pegol</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Subject complete C87035 study ( NCT00899678 ) Week 62 assessment participation C87035 terminate study stop UBC Subject complete assessment require Week 62/Visit 23 time termination Subjects maintain stable regimen concomitant medication Crohn 's Disease ( CD ) throughout study Subject complete C87035 study ( Week 62 Visit ) , terminate complete Week 62 assessment participation C87035 terminate study stop UCB complete assessment require Week 62/Visit 23 time termination</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Certolizumab Pegol</keyword>
	<keyword>CimziaÂ®</keyword>
	<keyword>Crohn 's Disease</keyword>
	<keyword>Children Adolescents Crohn 's Disease</keyword>
</DOC>